Testosterone replacement therapy and cardiovascular risk factors modification

References

• Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Baltimore longitudinal study of aging. Longitudinal effects of aging on serumtotal and free testosterone levels in healthy men. J Clin Endocrinol Metab 2001;86:724–773.
   PubMed Web of Science ®Google Scholar
• Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, Bemner WJ, McKinlay JB. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2002;87:589–598.
   PubMed Web of Science ®Google Scholar
• Liu PY, Beilin J, Meier C, Nguyen TV, Center JR, Leedman PJ, Seibel MJ, Eisman JA, Handelsman DJ. Age-related changes in serum testosterone and sex hormone binding globulin in Australian men: longitudinal analyses of two geographically separate regional cohorts. J Clin Endocrinol Metab 2007;92:3599–3603.
   PubMed Web of Science ®Google Scholar
• Morley JE, Kaiser FE, Perry HM 3rd, Patrick P, Morley PM, Stauber PM, Vellas B, Baumgartner RN. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in health older men. Metabolism 1997;46:410–413.
   PubMed Web of Science ®Google Scholar
• Nolten WE. Androgen deficiency in the aging male: when to evaluate and when to treat. Curr Urol Rep. 2000;1:313–319.
   PubMedGoogle Scholar
• Morley JE. Androgens and aging. Maturitas 2001;38:61–71.
   PubMed Web of Science ®Google Scholar
• Dominguez LJ, Barbagallo M, Morley J. The paradigm of life extension. J Am Med Dir Assoc 2010;11:457–458.
   Google Scholar
• Bain J. Department of Medicine, University of Toronto, Division of Endocrinology and Metabolism, Mount Sinai Hospital, Toronto, Ontario, Canada. Testosterone and the aging male: to treat or not to treat? Maturitas. 2010;66:16–22. Epub 2010 Feb 13.
   PubMed Web of Science ®Google Scholar
• Abellan van Kan G, Rolland YM, Morley JE, Vellas B. Frailty: toward a clinical definition. J Am Med Dir Assoc 2008;9:71–72.
   PubMed Web of Science ®Google Scholar
• Morley JE. Anorexia, sarcopenia, and aging. Nutrition 2001;17:660–663.
   PubMed Web of Science ®Google Scholar
• Chu LW, Tam S, Wong RL, et al. Bioavailable testosterone predicts a lower risk of Alzheimer's disease in older men. J Alzheimers Dis 2010;21:1335–1345.
   PubMed Web of Science ®Google Scholar
• Morley JE. Anorexia, weight loss, and frailty. J Am Med Dir Assoc 2010;11:225–228.
   PubMed Web of Science ®Google Scholar
• Morley JE. Anabolic steroids and frailty. J Am Med Dir Assoc 2010;11:533–536.
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, DeSimone G, Ferguson TB, Ford E, Furie K, Gillespie, et al. American Heart Association Statistics Committee and Stroke Statistics. Executive summary: heart disease and stroke statistics – 2010; Update: a report from the American Heart Association. Circulation 2010;121:948–954.
   PubMed Web of Science ®Google Scholar
• Turhan S, Tulunay C, Gulec S, Ozdol C, Kilickap M, Altin T, Gerede M, Erol C. The association between androgen levels and premature coronary artery disease in men. Coron Artery Dis 2007;18:159–162.
   PubMed Web of Science ®Google Scholar
• Khaw KT, Dowsett M, Folkerd E, Bingham S, Wareham N, Luben R, Welch A, Day N. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) prospective population study. Circulation 2007;116:2694–2701.
   PubMed Web of Science ®Google Scholar
• Khaw KT, Dowsett M, Folkerd E, Bingham S, Wareham N, Luben R, Welch A, Day N. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) prospective population study. Circulation 2007;116:2694–2701. Epub 2007 November 26.
   PubMed Web of Science ®Google Scholar
• Stanworth RD, Jones TH. Testosterone in obesity, metabolic syndrome and type 2 diabetes. Front Horm Res 2009;37:74–90 [review].
   PubMed Web of Science ®Google Scholar
• Cummings-Vaughn LA, Malmstrom TK, Morley JE, Miller DK. Testosterone is not associated with mortality in older African-American males. Aging Male 2010; August 4 [Epub ahead of print].
   Google Scholar
• Malkin CJ, Pugh PJ, Morris PD, Asif S, Jones TH, Channer KS. Low serum testosterone and increased mortality in men with coronary heart disease. Heart 2010;96:1821–1825.
   PubMed Web of Science ®Google Scholar
• English KM, Mandour O, Steeds RP, Diver MJ, Jones TH, Channer KS. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Euro Heart J. 2000;890–894.
   Google Scholar
• van den Beld AW, Bots ML, Janssen JAMLL, Pols HAP, Lamberts SWJ, Grobbee DE. Endogenous hormones and carotid atherosclerosis in elderly men. Am J Epid 2003;157:25–31.
   PubMed Web of Science ®Google Scholar
• Güder G, Frantz S, Bauersachs J, Allolio B, Ertl G, Angermann CE, Störk S. Low circulating androgens and mortality risk in heart failure. Heart. 2010;96:504–509; Epub 2009 Oct 28.
   PubMed Web of Science ®Google Scholar
• Charbit B, Christin-Maître S, Démolis JL, Soustre E, Young J, Funck-Brentano C. Effects of testosterone on ventricular repolarization in hypogonadic men. Am J Cardiol 2009;103:887–890. Epub 24 Jan 2009.
   PubMed Web of Science ®Google Scholar
• Wang C, Nieschlag E, Swerdloff RS, Behre H, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfield B, Morales A, et al. ISA, ISSAM, EAU, EAAS and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male 2009;12:5–12.
   PubMed Web of Science ®Google Scholar
• Traish AM, Abdou R, Kypreos KE. Androgen deficiency and atherosclerosis: the lipid link. Vascul Pharmacol 2009;51:303–313.
   PubMed Web of Science ®Google Scholar
• Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006;154:899–906.
   PubMed Web of Science ®Google Scholar
• Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med 2004;34:513–554.
   PubMed Web of Science ®Google Scholar
• Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS, Jones TH. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab 2004;89:3313–3318.
   PubMed Web of Science ®Google Scholar
• Zumoff B, Strain GW, Miller LK, Rosner W, Senie R, Seres DS, Rosenfeld RS. Plasma free and non sex-hormone-binding-globulin-bound testosterone are decreased in obese men in proportion to their degree of obesity. J Clin Endocrinol Metab 1990;71:929–931.
   PubMed Web of Science ®Google Scholar
• Pasquali R, Casimirri F, Cantobelli S, Melchionda N, Morselli Labate AM, Fabbri R, Capelli M, Bortoluzzi L. Effect of obesity and body fat distribution on sex hormones and insulin in men. Metabolism 1991;40:101–104.
   PubMed Web of Science ®Google Scholar
• Vitale C, Mendelsohn ME, Rosano GM. Gender differences in the cardiovascular effect of sex hormones. Nat Rev Cardiol 2009;6:532–542.
   PubMed Web of Science ®Google Scholar
• Zitzmann M. Testosterone deficiency, insulin resistance and the metabolic syndrome. Nat Rev Endocrinol 2009;5:673–681.
   PubMed Web of Science ®Google Scholar
• Kalyani RR, Dobs AS. Androgen deficiency, diabetes, and the metabolic syndrome in men. Curr Opin Endocrinol Diabetes Obes 2007;14:226–234.
   PubMedGoogle Scholar
• Selvin E, Feinleib M, Zhang L, Rohrmann S, Rifaii N, Nelson WG, Dobs A, Basaria S, Golden SH, Platz EA. Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 2007;30:234–238.
   PubMed Web of Science ®Google Scholar
• Haffner SM, Valdez RA, Stern MP, Katz MS. Obesity, body fat distribution and sex hormones in men. Int J Obes 1993;17:634–639.
   Web of Science ®Google Scholar
• Phillips GB. Relationships in men of sex hormones, insulin, adiposity, and risk factors for myocardial infarction. Metabolism 2003;52:784–790.
   PubMed Web of Science ®Google Scholar
• Khaw KT, Barrett-Connor E. Blood pressure and endogenous testosterone in men: an inverse relationship. J Hypertens 1988;6:329–332.
   PubMed Web of Science ®Google Scholar
• Fogari R, Preti P, Zoppi A, Fogari E, Rinaldi A, Corradi L, Mugellini A. Serum testosterone levels and arterial blood pressure in the elderly. Hypertens Res 2005;28:625–630.
   Google Scholar
• Webb CM, Elkington AG, Kraidly MM, Keenan N, Pennell DJ, Collins P. Effects of oral testosterone treatment on myocardial perfusion and vascular function in men with low plasma testosterone and coronary heart disease. Am J Cardiol 2008;101:618–624.
   PubMed Web of Science ®Google Scholar
• Bernini G, Versari D, Moretti A, Virdis A, Ghiadoni L, Bardini M, Taurino C, Canale D, Taggei S, Salvetti A. Vascular reactivity in congenital hypogonadal men before and after testosterone replacement therapy. J Clin Endocrinol Metab 2006;91:1691–1697.
   PubMed Web of Science ®Google Scholar
• Yaron M, Greenman Y, Rosenfeld JB, Izhakov E, Limor R, Osher E, Shenkerman G, Tordjman K, Stern N. Effect of testosterone replacement therapy on arterial stiffness in older hypogonadal men. Eur J Endocrinol 2009;160:839–846.
   PubMed Web of Science ®Google Scholar
• Reckelhoff JF, Zhang H, Granger JP. Testosterone exacerbates hypertension and reduces pressure-natriuresis in male spontaneously hypertensive rats. Hypertension 1998;31:435–439.
   PubMed Web of Science ®Google Scholar
• Yanes LL, Sartori-Valinotti JC, Iliescu R, Romero DG, Racusen LC, Zhang H, Reckelhoff JE. Testosterone-dependent hypertension and upregulation of intrarenal angiotensinogen in Dahl salt-sensitive rats. Am J Physiol Renal Physiol 2009;296:F771–F779.
   Google Scholar
• Vakil RJ. An evaluation of testosterone propionate therapy in cases of angina pectoris. Ind Med Gaz 1949;84:83–88.
   Google Scholar
• Ganelina IE. On treatment of angina pectoris with testosterone [article in undetermined language]. Ter Arkh 1951;23:28–36.
   Google Scholar
• Aubertin E. Testosterone propionate in the treatment of angina pectoris [article in undetermined language]. J Med Bord 1953;130:686–687.
   Google Scholar
• Muderrisoglu B. The value of testosterone proprionate (perandrone) in the treatment of heart disease and angina pectoris [article in un-determined language]. Brux Med 1953;33:969–980.
   Google Scholar
• Gmachl E, Hortnagl W. The treatment of angina pectoris with laevadenyl and testoviron [German]. Wien Klin Wochenschr 1954;66:593–595.
   Google Scholar
• Wu SZ, Weng XZ. Therapeutic effects of an androgenic preparation on myocardial ischemia and cardiac function in 62 elderly male coronary heart disease patients. Chin Med J 1993;106:415–418.
   PubMed Web of Science ®Google Scholar
• Jaffe MD. Effect of testosterone cypionate on postexercise ST segment depression. Brit Heart J 1977;39:1217–1222.
   PubMedGoogle Scholar
• English KM, Steeds RP, Jones TH, Diver MJ, Channer KS. Low-dose transdermal therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation 2000;102:1906–1911.
   PubMed Web of Science ®Google Scholar
• Malkin CJ, Pugh PJ, Morris PD, Kerry KE, Jones RD, Jones TH, Channer KS. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart 2004;90:871–876.
   PubMed Web of Science ®Google Scholar
• Paulusinski R, Barud W, Bilan A, Witczak A, Myslinski W, Hanzlik J. Effect of dihydrotestosterone treatment on exercise induced ischemia in men with stable ischemic heart disease [Polish] Pol Merkur Lekarski 2000;9:533–534.
   Google Scholar
• Cornoldi A, Caminiti G, Marazzi G, Vitale C, Patrizi R, Volterrani M, Miceli M, Volterrani M, Miceli M, Fini M, Spera G, Rosano G. Effects of chronic testosterone administration on myocardial ischemia, lipid metabolism and insulin resistance in elderly male diabetic patients with coronary artery disease. Int J Cardiol 2010;142:50–55.
   PubMed Web of Science ®Google Scholar
• Mathur A, Malkin C, Saeed B, Muthusamy R, Jones TH, Channer K. Long-term benefits of testosterone replacement therapy on angina threshold and atheroma in men. Eur J Endocrinol 2009;161:443–449.
   PubMed Web of Science ®Google Scholar
• English KM, Jones RD, Jones TH, Morice AH, Channer KS. Testosterone acts as a coronary vasodilator by a calcium antagonistic action. J Endocrinol Invest 2002;25:455–458.
   PubMedGoogle Scholar
• Scragg JL, Dallas ML, Peers C. Molecular Requirements for L-type Ca2+ channel blockade by testosterone. Cell Calcium 2007;42:11–15.
   PubMed Web of Science ®Google Scholar
• Heidenreich PA, Fonarow GC. Are registry hospitals different? A comparison of patients admitted to hospitals of a commercial heart failure registry with those from national and community cohorts. Am Heart J 2006;152:935–939.
   PubMed Web of Science ®Google Scholar
• Pascual-Figal DA, Tornel PL, Nicolás F, Sánchez-Más J, Martínez MD, Gracia MR, Garrido IP, Ruipérez JA, Valdés M. Sex hormone-binding globulin: a new marker of disease severity and prognosis in men with chronic heart failure. Rev Esp Cardiol. 2009;62:1381–1387.
   PubMedGoogle Scholar
• Omran ML, Morley JE. Assessment of protein energy malnutrition in older persons, part I: history, examination, body composition, and screening tools. Nutrition 2000;16:50–63.
   PubMed Web of Science ®Google Scholar
• Omran ML, Morley JE. Assessment of protein energy malnutrition in older persons, Part II: laboratory evaluation. Nutrition 2000;16:131–140.
   PubMed Web of Science ®Google Scholar
• Güder G, Frantz S, Bauersachs J, Allolio B, Ertl G, Angermann CE, Störk S. Low circulating androgens and mortality risk in heart failure. Heart 2010;96:504–509; doi:10.1136/hrt.2009.181065.
   PubMed Web of Science ®Google Scholar
• Caminiti G, Volterrani M, Iellamo F, Marazzi G, Massaro R, Miceli M, Mammi C, Piepoli M, Fini M, Rosano GM. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol 2009;54:919–927.
   PubMed Web of Science ®Google Scholar
• Jankowska EA, Filippatos G, Ponikowska B, Borodulin-Nadzieja L, Anker SD, Banasiak W, Poole-Wilson PA, Ponikowski P. Reduction in circulating testosterone relates to exercise capacity in men with chronic heart failure. J Card Fail 2009;15:442–450; Epub 10 Feb 2009.
   PubMed Web of Science ®Google Scholar
• Somani B, Khan S, Donat R. Screening for metabolic syndrome and testosterone deficiency in patients with erectile dysfunction: results from the first UK prospective study. BJU Int 2010; 106:688–690.
   Google Scholar
• Borst SE, Quindry JC, Yarrow JF, Conover CF, Powers SK. Testosterone administration induces protection against global myocardial ischemia. Horm Metab Res 2010;42:122–129; Epub 27 October 2009.
   PubMedGoogle Scholar
• Li ZB, Wang J, Wang JX, Chen XM, Jiang SS. Testosterone therapy improves cardiac function of male rats with right heart failure. Zhonghua Nan Ke Xue 2009;15:994–1000.
   PubMedGoogle Scholar
• Pan Y, Zhang H, Acharya AB, Patrick PH, Oliver D, Morley JE. Effect of testosterone on functional recovery in a castrate male rat stroke model. Brain Res 2005;1043:195–204.
   PubMed Web of Science ®Google Scholar
• Pecori Giraldi F, Toja PM, Filippini B, Michailidis J, Scacchi M, Stramba Badiale M, Cavagnini F. Increased prevalence of prolonged QT interval in males with primary or secondary hypogonadism: a pilot study. Int J Androl 2010;33:e132–e138; Epub 11 Sept 2009.
   Google Scholar
• Charbit B, Christin-Maitre S, Demolis JL, Soustre E, Young J, Funck-Frentano C. Effects of testosterone on ventricular repolarization in hypogonadic men. Am J Cardiol 2009;103: 887–890.
   PubMed Web of Science ®Google Scholar
• Lai J, Zhou D, Xia S, Shang Y, Want L, Zheng L, Zhu J. Reduced testosterone levels in males with lone atrial fibrillation. Clin Cardiol 2009;32:43–46.
   PubMed Web of Science ®Google Scholar
• Liu T, Shehata M, Li G, Wang X. Androgens and atrial fibrillation: Friends or foes? Int J Cardiol 2010;145: 365–367.
   PubMed Web of Science ®Google Scholar
• Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, Eder R, Tennstedt S, Ullor J, Zhang A, et al. Adverse events associated with testosterone administration. N Engl J Med 2010;363:109.
   PubMed Web of Science ®Google Scholar
• Omran ML, Morley JE. Assessment of protein energy malnutrition in older persons. Part II: laboratory evaluation. Nutrition 2000;16:131–140.
   PubMed Web of Science ®Google Scholar
• Ahmed A, Jones L, Hays CL. DEFEAT heart failure: assessment and management of heart failure in nursing homes made easy. J Am Med Dir Assoc 2008;9:383–389.
   Google Scholar
• Morley JE. Developing novel therapeutic approaches to frailty. Curr Pharm Des 2009;15:3384–3395.
   PubMed Web of Science ®Google Scholar
• Gobbens RJ, van Assen MA, Luijkx KG, Wijnen-Sponselle MT, Schols JM. Determinants of frailty. J Am Med Dir Assoc 2010;11:356–364.
   PubMed Web of Science ®Google Scholar
• van Kan GA, Rolland Y, Bergman H, Abellan van Kan G, Rolland Y, Bergman H, Morley JE, Kritchevsky SB, Vellas B. The IANA task force on frailty assessment of older people in clinical practice. J Nutr Hlth Aging 2008;12:29–37.
   PubMed Web of Science ®Google Scholar
• Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, Bhasin S. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 2005;60:1451–1457.
   PubMed Web of Science ®Google Scholar
• Hajjar RR, Kaiser FE, Morley JE. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J Clin Endocrinol Metab 1997;82:3793–3796.
   PubMed Web of Science ®Google Scholar
• Pugh PJ, Jones RD, West JN, Jones TH, Channer KS. Testosterone treatment for men with chronic heart failure. Heart 2010;90:446–447.
   Google Scholar
• Malkin CJ, Pugh PJ, West JN, van Beek EJ, Jones TH, Channer KS. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trail. Eur Heart J 2006;27:57–64.
   PubMed Web of Science ®Google Scholar
• Srinivas-Shankar U, Roberts SA, Connolly MJ, O'Connell MD, Adams JE, Oldham JA, Wu FC. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2010;95:639–650.
   PubMed Web of Science ®Google Scholar
• Kenny AM, Kleppinger A, Annis K, Rathier M, Browner B, Judge JO, McGee D. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. J Am Geriatr Soc 2010;58:1134–1143.
   PubMed Web of Science ®Google Scholar
• Chapman IM, Visvanathan R, Hammond AJ, Morley JE, Field JB, Tai K, Belobrajdic DP, Chen RY, Horowitz M. Effect of testosterone and a nutritional supplement, alone and in combination, on hospital admissions in undernourished older men and women. Am J Clin Nutr 2009;89:880–889.
   PubMed Web of Science ®Google Scholar
• Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males. Eur J Endocrinol 2008;159:507–514.
   PubMed Web of Science ®Google Scholar
• Morley JE, Haren MT, Rolland Y, Kim MJ. Frailty. Med Clin North Am 2006;90:837–847.
   PubMed Web of Science ®Google Scholar
• Morley JE. Should frailty be treated with testosterone? Aging Male 2011;14:1–3.
   Google Scholar
• Morley JE, Argiles JM, Evans WJ, Bhasin S, Cella D, Deutz NE, Doehner W, Fearon KC, Ferrucci L, Hellerstein MK, et al. Nutritional recommendations for the management of sarcopenia. J Am Med Dir Assoc 2010;11:391–396.
   PubMed Web of Science ®Google Scholar
• Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, Bhasin S. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 2005;60:1451–1457.
   PubMed Web of Science ®Google Scholar